Chinese pharmaceutical company Zhejiang Hisun Pharmaceutical said that it received permission from the country’s authorities to sell the drug Favipiravir as a potential drug for coronavirus. Free News reported with reference to Reuters.

The company said that it will continue clinical trials of the drug after it appears on the market in a new quality.

Portal concerning the statement of the Director Of the center for biotechnological development under the Chinese Ministry of science and technology of the PRC, Zhang Xinmin notes that 70 patients participated in the clinical trials of Favipiravir. According to initial data, the drug has “relatively obvious effectiveness” and is low likely to cause side effects. Several other drugs are undergoing similar tests.

According to the world health organization, the first tests of a vaccine created specifically against the COVID-2019 virus will begin on humans in four to five months. At the same time, it will be possible to proceed directly to the use of the vaccine in about a year and a half.

More than 68 thousand people have been infected with the coronavirus. The number of deaths due to the epidemic of the disease is close to 1.7 thousand people.